GSK Targets 85 Percent Of World’s Smokers With Cessation Products
This article was originally published in PharmAsia News
GlaxoSmithKline plans a big marketing expansion in the emerging markets of the world, particularly in China and India. The firm is leading with its smoking-cessation drugs, targeting 20 new markets as it seeks to increase sales in the developing world. GSK markets lozenges and patches to help smokers quit, but has not been marketing them heavily outside of the developed world. Current statistics indicate that most of the world's smokers live in developing nations only now mounting anti-smoking campaigns. GSK plans to reach 85 percent of the smokers in the world within five years. (Click here for more - a subscription may be required
You may also be interested in...
Diagnostics company Bodysphere had to retract an announcement that it had received an emergency use authorization from the US FDA for a COVID-19 serologic test. See why Bethany Hills, an attorney with law firm Morrison & Foerster, says this may be a cautionary tale for other manufacturers.
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
Japanese ICT giant applies novel advanced computing techniques with a US venture partner to more rapidly identify lead molecules from a huge virtual space.